Young Blood Plasma Administration to Fight Alzheimer's Disease?
Despite decades of intensive research, no drugs can cure or even stabilize Alzheimer's disease (AD). Current pharmacological treatments only partially mask the symptoms while the disease progresses within the brain. Finding a preventive measure or a cure for people with AD is indeed a worldwide urge...
| Publicado en: | Rejuvenation Research Vol. 21; no. 2; pp. 178 - 182 |
|---|---|
| Autor principal: | |
| Formato: | Journal Article |
| Publicado: |
Mary Ann Liebert, Inc.
Apr2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129124583&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 129124583 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15491684 1E3T jtl: Rejuvenation Research issn: 15491684 maglogo: N pubinfo: dt: Apr2018 vid: 21 iid: 2 pid: 1365 pub: Mary Ann Liebert, Inc. place: New Rochelle, New York artinfo: ui: 129124583 129124583 NLM28384033 10.1089/rej.2017.1940 NLM28384033 129124583 ppf: 178 ppct: 4 formats: tig: atl: Young Blood Plasma Administration to Fight Alzheimer's Disease? aug: au: Aicardi, Giorgio affil: Department for Life Quality Studies, University of Bologna, Bologna, Italy. sug: subj: Alzheimer's Disease Metabolism Blood Component Transfusion Methods Alzheimer's Disease Therapy Memory Disorders Prevention and Control Models, Biological Signal Transduction Male Mice Animals Female Age Factors Male Female ab: Despite decades of intensive research, no drugs can cure or even stabilize Alzheimer's disease (AD). Current pharmacological treatments only partially mask the symptoms while the disease progresses within the brain. Finding a preventive measure or a cure for people with AD is indeed a worldwide urgent priority. A recent interesting study by T. Wyss-Coray's research group provides the first evidence that exposure to young blood or plasma can reverse some AD-related molecular and behavioral alterations. Heterochronic parabiosis (shared blood circulation) of AD transgenic mice with young healthy mice did not reduce amyloidosis and microglial activation in AD mice, but reversed the loss of synaptophysin and calbindin (critical synaptic proteins, indicators of cognitive decline in AD) in the dentate gyrus, and the abnormal expression, in the hippocampus, of many genes involved in key neuronal signaling pathways. Moreover, repeated intravenous administration of plasma from young healthy mice to AD mice reversed the excessive phosphorylation of hippocampal extracellular signal-regulated kinase (ERK), and improved spatial working memory and associative memory. Although observations in mouse models of AD might not necessarily extrapolate to humans, this preclinical study provides the first demonstration that young plasma has potential therapeutic properties, by ameliorating aspects of the disease that are present in AD patients. Clinical trials are already under way. If young plasma transfusion will be effective in AD patients, it will be important to identify the key factors responsible for the positive effects, as they might lead to the development of molecule interventions with a better efficacy/risk profile. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|